Newsroom



News

PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.



  • July 25, 2016
  • Pulmonary Hypertension in Newborns Might Be Treated at Early Stage Using Ecocardiography
  • (Pulmonary Hypertension news) Researchers at Baylor College of Medicine in Houston, Texas, induced oxidative stress and inflammation, the two main factors contributing to PH development, in a group of newborn mice by exposing them to very high levels of oxygen (70%) for 14 days. A control group was exposed to 21% oxygen or regular air.
  •   
  • July 22, 2016
  • Effect of Warfarin Treatment on Survival of Patients With PAH in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)
  • (AHA Journals) No significant survival advantage was observed in IPAH patients who started warfarin. In SSc-PAH patients, long-term warfarin was associated with poorer survival than in patients not receiving warfarin, even after adjusting for confounders
  •   
  • July 21, 2016
  • Pediatric Pulmonary Hypertension
  • (Journal of the American College of Cardiology) Children with PAH are currently treated with targeted PAH drugs and may benefit from these new therapies. This review provides an overview of recent information regarding the current approach and diagnostic classification of PAH in children as based on discussions and recommendations from the Pediatric Task Force of the 5th World Symposium on Pulmonary Hypertension (WSPH) in Nice, France (2013).
  •   
  • July 20, 2016
  • Protein target may block deadly arterial remodeling in pulmonary hypertension
  • (Medical Xpress) Scientists believe that a protein, galectin-3, highly expressed in pulmonary hypertension is a major culprit that transforms the thin, flexible vasculature of the lungs into thick, dysfunctional blood vessels, as well as a potentially effective new treatment target.  They also have early evidence that a drug already in human studies for liver fibrosis can block or turn around early disease, said Dr. David Fulton, director of the Vascular Biology Center at the Medical College of Georgia at Augusta University.
  •   
  • July 19, 2016
  • Pulmonary Hypertension
  • (AHA Journals) Many people affected by pulmonary hypertension are able to lead productive and satisfying lives, in part because of advances in medical care and treatments. It is important that those affected by this illness keep themselves informed about the problem and understand the available treatments to improve their health and quality of life. They need to know that, without treatment, pulmonary hypertension can be a life-threatening illness.
  •   
  • July 18, 2016
  • New Mifcare PAH Therapy Shows Beneficial Results, According to Pre-Clinical Animal Test
  • (Pulmonary Hypertension News) The team of researchers at Inserm U999, led by Dr. Christophe Guignabert, showed that MFC1040 is able to reverse the vascular remodeling (changes) seen in the lungs of rat models of PAH, by inhibiting a protein called macrophage migration inhibitory factor (MIF).
  •   
  • July 16, 2016
  •  Online breath test aims to diagnose lung problems earlier and reduce workload
  • (GP) The British Lung Foundation (BLF) launched the Listen to your lungs campaign to help find the ‘missing millions’ of people living with undiagnosed lung disease.
  •   
  • July 14, 2016
  • Oxygen Therapy Seen to Harm Lungs of Newborns with Pulmonary Hypertension
  • (Pulmonary Hypertension News) When a child is born and brought into the oxygen-rich environment of our atmosphere, the lungs, inactive until that time, go through extensive changes.
  •   
  • July 13, 2016
  • Effectiveness of PAH Therapy Boosted by Use of Nanoparticles in Animal Study
  • (Pulmonary Hypertension News) Ethyl pyruvate has been shown to improve survival and/or ameliorate organ dysfunction, including in mouse models of acute lung injury. Ways of enhancing its delivery might prolong its effectiveness, and decrease the frequency of its administration.
  •   
  • Pulmonary Hypertension and ‘The Spoon Theory’
  • (Pulmonary Hypertension News (blog)) Living with limitations as a young adult can be very challenging. Even after two years, my body at times still feels foreign to me
  •   
  • July 12, 2016
  • Likelihood of PAH in Scleroderma Patients May Be Evident in Specific Autoantibodies
  • (Pulmonary Hypertension News) Researchers in Italy developed a clear way of exploring differences in autoantibodies to predict which scleroderma patients are likely to develop pulmonary arterial hypertension (PAH), improving their chances of getting appropriate treatment before changes in their lung blood vessels take place.
  •   
  • July 11, 2016
  • Actelion to Start a Phase 3 Trial Evaluating Opsumit as Treatment for Children with PAH
  • (Pulmonary Hypertension News) Opsumit, an orally available endothelin receptor antagonist (ERA), is currently approved in both Europe and the U.S. to treat progression in adults with PAH (WHO Group I in the U.S. and WHO Group II-III in Europe).
  •   
  • Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia.
  • (PubMed) When bronchopulmonary dysplasia (BPD) is complicated by pulmonary hypertension (PH), morbidity and mortality are significantly increased. BPD-associated PH is not included in the current indications for PH medications. However, limited data demonstrate hemodynamic improvement and decreased mortality with PH-specific treatment. This report describes our 6-year experience treating BPD-associated PH with PH medications, mainly sildenafil.
  •   
  • July 8, 2016
  • Pulmonary Arterial Hypertension Associated with Adult Congenital Heart Disease, when Inoperable becomes Operable: A Case Report
  • (Journal of Pulmonary & Respiratory Medicine) Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is one of the most common forms of pulmonary arterial hypertension (PAH). Unlike the other forms, PAH-CHD can be treated surgically closing the extra- or intracardiac shunt if the shunt is left-to-right and the pulmonary vascular resistance (PVR) is low enough (<2,3-operable, 2,3-4,6 WU-borderline operable). If the PAH postoperatively persists the prognosis is even worse than for non-operated patients. Due to the previously mentioned fact the criteria for operability in such cases are often discussed. We report a case of a 54-year-old man who suffers from coronary artery disease (SYNTAX score-23,5) and PAH-CHD. As the patient required coronary artery bypass grafting (CABG) surgery, the atrial septal defect (ASD) was closed (surgically with a patch followed by transcatheter closure with an occluder) as well despite the fact that according to the current guidelines his pulmonary vascular resistance (4,7 WU) was considered too high for the defect to be operable. The patient was given PAH-specific treatment preoperatively in order to lower his PVR. This article describes the case and discusses the disease, its history, the new classification, diagnostics and treatment options.
  •   
  • July 7, 2016
  • Focus on Research: Pulmonary hypertension studies
  • (Emory Daily Pulse) A team of investigators at the Atlanta VA Medical Center led by Mike Hart, MD and Roy Sutliff, PhD (Emory Division of Pulmonary, Allergy, Critical Care and Sleep Medicine) is researching multi-dimensional strategies to address pulmonary hypertension (PH), or high blood pressure in the lungs. The goal of this highly collaborative team is to better define the underlying causes of this devastating lung disease in the hope that these discoveries will lead to better and more effective therapies.
  •   
  • July 6, 2016
  • Hepatoma Derived Growth Factor Predicts Disease Severity and Survival in PAH
  • (ATS Journal) We sought to assess the relationship of serum Hepatoma Derived Growth Factor (HDGF) and PAH disease severity and survival. Methods: Using a newly developed enzyme-linked immunosorbent assay (ELISA), we evaluated circulating HDGF levels in two independent PAH cohorts and two different characterized control cohorts
  •   
  • Treating autoimmune disease without harming normal immunity
  • (Science Daily) With potentially major implications for the future treatment of autoimmunity and related conditions, scientists have found a way to remove the subset of antibody-making cells that cause an autoimmune disease, without harming the rest of the immune system. 

    Current therapies for autoimmune disease, such as prednisone and rituximab, suppress large parts of the immune system, leaving patients vulnerable to potentially fatal opportunistic infections and cancers.

    The Penn researchers demonstrated their new technique by successfully treating an otherwise fatal autoimmune disease in a mouse model, without apparent off-target effects, which could harm healthy tissue. The results are published in an online First Release paper in Science.
  •   
  • July 5, 2016
  • 7 Medications to Treat Pulmonary Hypertension
  • (Pulmonary Hypertension News) According to the Mayo Clinic, discover which type of treatments or medications are available to help treat pulmonary hypertension.
  •   
  • Anemia and Iron Deficiency Linked to Mortality in HF
  • (MedPage Today) Anemia and iron deficiency are both potential therapeutic targets among patients with HF, the researchers noted, because "anemia, regardless of its cause, will increase cardiac demand, which could have a deleterious effect on symptoms and prognosis. Iron deficiency may also be important in HF because it is an essential component of myoglobin and the mitochondrial respiratory chain."
  •   
  • July 3, 2016
  • The news team will be back on July 5th.
  •   
  • July 2, 2016
  • PAH May Be Linked to Increased Sensitivity to DNA Damage
  • (Pulmonary Hypertension News) Although little is known about the events that lead to the development of PAH, oxidative stress and inflammation are thought to play major roles in promoting vascular remodeling. Because oxidative stress and inflammation are known to favor DNA damage, it is possible that the abnormal cell proliferation observed in vascular remodeling are caused mostly by dysfunctional DNA-damage response mechanisms.
  •   
  • July 1, 2016
  • EMA warns against use of riociguat in PH-IIP type pulmonary hypertension
  • (Today's GP) Although the drug is not authorised for use in PH-IIP patients, the EMA has issued the recommendation following the early termination of a phase II clinical trial, RISE-IIP, investigating the effects of Adempas in this patient population.
  •   
  • June 30, 2016
  • Questionnaire for PAH Patients to Help Determine Quality of Life
  • (Pulmonary Hypertension News) The questionnaire, called PAH-SYMPACT, was created following guidance from the U.S. Food and Drug Administration (FDA) to include patient reported outcomes as secondary endpoints in clinical trials.
  •   
  • June 29, 2016
  • Approved Drug, 4-PBA, Eased ER Stress and Artery Pressure in PAH Rat Model Study Reports
  • (Pulmonary Hypertension News) A drug approved for a genetic condition called urea cycle disorder — sodium 4-phenylbutyric acid (4-PBA) — shows a protective effect for pulmonary arterial hypertension (PAH) by decreasing pulmonary artery pressure and mean right ventricular pressure in a PAH rat model
  •   
  • Texas Children's Hospital ranks #1 nationally in pulmonology among nation's best pediatric institutions by U.S. News & World Report
  • (PR Newswire) Each year, U.S. News ranks pediatric hospitals overall, as well as ranks the top 50 pediatric hospitals across 10 major subspecialties.
  •   
  • June 28, 2016
  • Positive Interim Results from PAH Extension LARIAT Trial Reported by Reata
  • (Pulmonary Hypertension News) The study aims to determine the recommended dose range, assessing the change from baseline in a six-minute walking distance (6MWD, a test for exercise capacity), and to determine the effect of the drug in PAH associated with connective tissue disease, interstitial lung disease, and from unknown causes.
  •   
  • Improvements needed in end-of-life care for patients with organ failure
  • (EuyrekAlert) Historically, efforts to improve end-of-life care have focused primarily on patients with cancer. But few studies have looked at the quality of end-of-life care for patients with other serious illnesses, such as lung, kidney or heart failure or dementia
  •   
  • June 27, 2016
  • Blood test shows promise in gauging severity of pulmonary arterial hypertension
  • (Science Daily) Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs. Their findings, described online June 2 in American Journal of Respiratory and Critical Care Medicine, could, they say, eventually lead to a more specific, noninvasive test for pulmonary arterial hypertension that could help doctors decide the best treatment for the disease.
  •   

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives